证券代码：301201 证券简称：诚达药业 诚达药业股份有限公司 | 投资者关系活动类别 □√ | 特定对象调研 分析师会议 ☐ | | --- | --- | | ☐ | 媒体采访 业绩说明会 ☐ | | ☐ | 新闻发布会 路演活动 ☐ | | □√ | 现场参观 | | ☐ 国金证券 | 其他（请文字说明其他活动内容） 方程嫣、华鑫证券 胡博新、吴景欢、中信证券 彭康、国 | | 元证券 | 马云涛、国泰海通 陈铭、东方证券 张坤、九方智投 朱仕 | | 参与单位名称及人员姓名 | 平、东方红资管 徐宏、南土资产 许智涵、交银施罗德 朱亦宁、永 | | 赢基金 | 张晓榕、博翱投资 任毅 | | 时间 | 2025年12月2日 10:00-11:30 | | 地点 | 公司会议室、展厅（部分人员通过腾讯会议参与） | | | 副总经理、董事会秘书 杨晓静 | | 上市公司接待人员姓名 | 证券事务代表 吴忠杰 | | | 1.公司布局小核酸业务的契机和目前的进展？ 答：小核酸药物中间体是公司CDMO业务的延伸，契机主要是公 | | 投资者关系活动主要内容 | 司的海外代理推广小核酸业务，公司通过技术合作 ...

Summary of Jiuzhou Pharmaceutical Conference Call Company Overview - **Company**: Jiuzhou Pharmaceutical - **Industry**: CDMO (Contract Development and Manufacturing Organization) Key Points and Arguments Financial Performance - Jiuzhou Pharmaceutical reported a revenue growth of **42%** in the first three quarters of 2025, driven by sales growth and improved gross margins [2][3] - Operating cash flow increased by over **100%**, reaching **1.34 billion RMB**, due to timely collection of payments [2][3] - For Q3 2025, the company achieved a net profit of **220 million RMB**, a **42%** year-on-year increase, attributed to sales growth and higher product margins [3] Market Trends and Industry Outlook - The CDMO industry is expected to rebound starting Q4 2024, influenced by a declining interest rate cycle and improved investment environment [2][7] - Jiuzhou Pharmaceutical's **80%** of orders come from overseas, with strong business certainty from major clients [7] - The Japanese and Korean markets are projected to maintain a growth rate of **30%** over the next 1-2 years, while the U.S. market is expected to see contract amounts grow by over **30%** [2][7] Production Capacity and Utilization - New factory capacity utilization exceeded expectations, with the Taizhou factory operating at near full capacity with **17 projects** simultaneously [2][6] - The company plans to maintain a stable expense ratio for the year, with a slight decrease in R&D expense ratio anticipated [2][14] Product Development and Pipeline - The company has introduced over **30** high-value projects in the formulation sector, with **22** projects in the generic drug pipeline, of which **8** have been approved and **9** submitted for approval [4][9] - The Taizhou factory is expected to start production in November 2025, with an annual capacity of **800 kg**, and **30-40%** of this capacity already has confirmed orders [8] Strategic Initiatives - Jiuzhou Pharmaceutical is focusing on enhancing collaboration with core clients and actively expanding its customer base [2][3] - The company is also pursuing mergers and acquisitions to establish overseas commercial production bases [4][13][16] Challenges and Risks - The raw material prices have seen a decline, but an improvement is expected in Q4 2025 [4][15] - The company faces challenges in the raw material sector due to domestic overcapacity and intense competition, leading to price fluctuations [15] Future Plans - Capital expenditure for 2025 is projected to be controlled within **1 billion RMB**, with a focus on talent acquisition in emerging fields such as peptides and small molecules [17] - Jiuzhou Pharmaceutical aims to establish high-automation overseas commercial bases, with an estimated project scale of **100 million USD** [20] Asset Impairment - The company anticipates no significant changes in asset impairment for 2025, maintaining overall stability [21] Additional Important Information - Jiuzhou Pharmaceutical has established a strong presence in the Japanese market, being a core supplier to over half of the top ten pharmaceutical companies [13] - The company is actively working on expanding its capabilities in the peptide and small nucleic acid sectors, with plans for mid-scale production capacity [8][12]